Researchers reanalyze COVID RECOVERY trial data on tocilizumab

By | June 24, 2021
A Bayesian analysis of the RECOVERY trial suggests the immunosuppressive drug tocilizumab can reduce deaths in hospitalized COVID-19 patients taking corticosteroids as well as patients on oxygen or non-invasive ventilation and likely increases hospital discharge rates. However, it is not clear if patients on invasive ventilation also benefit.